529 related articles for article (PubMed ID: 17145652)
1. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
2. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
5. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
6. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
7. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
[TBL] [Abstract][Full Text] [Related]
8. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
10. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
Verit FF
Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
13. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
14. Retinol-binding protein in nonobese women with polycystic ovary syndrome.
Lee JW; Im JA; Lee DC; Lee HR; Shim JY
Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278
[TBL] [Abstract][Full Text] [Related]
15. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
16. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Song J; Shen H; Li J; Huang Z; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
[TBL] [Abstract][Full Text] [Related]
17. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Chou KH; von Eye Corleta H; Capp E; Spritzer PM
Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
[TBL] [Abstract][Full Text] [Related]
18. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
19. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
[TBL] [Abstract][Full Text] [Related]
20. Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Panidis D; Farmakiotis D; Rousso D; Katsikis I; Delkos D; Piouka A; Gerou S; Diamanti-Kandarakis E
Eur J Intern Med; 2008 Oct; 19(6):406-12. PubMed ID: 18848173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
